AI diagnostic leadership IMVARIA has FDA-authorized AI diagnostic tools for ILD and IPF (Fibresolve) and is expanding AI biomarker development across oncology, pulmonology, and immunology, signaling opportunities to partner with hospitals and clinics seeking advanced diagnostic capabilities and digital biomarkers.

Clinical collaboration Partnerships with Mayo Clinic and multi-site clinical experience showcased at ATS 2025 indicate strong interest from major academic and research centers, suggesting sales targets in academic medical centers, cancer centers, and large health systems pursuing AI-powered diagnostics.

SBIR funding momentum NIH SBIR Phase I grant awarded in 2025 underscores potential for government-funded deployments and grants, providing a pathway for co-financed projects with health systems and research institutes seeking scalable AI diagnostic solutions.

IP and regulatory edge FDA Breakthrough Device designation and FDA authorization for Fibresolve position IMVARIA with a regulatory moat, making it a compelling partner for hospitals aiming to accelerate compliant integration of AI-driven diagnostic tools into ILD/IPF workflows.

SMB to enterprise fit Current revenue indicates a lean, high-potential growth profile with room to scale into mid-market and enterprise health systems, offering repeatable AI-driven diagnostic services, case referrals, and managed analytics engagements as a scalable revenue model.